Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
11. Dezember 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight DelveInsight’s analysts estimate that the...
Innovative Advances in Alcohol Use Disorder Therapeutics Report 2024: In-depth Insights on 30+ Companies and 30+ Pipeline Drugs
21. November 2024 04:10 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A new comprehensive report unveils a...
Alcohol Use Disorder Industry Forecast to Reach $1.88 Billion by 2030 - Telemedicine and Mobile Applications Present Lucrative Business Opportunities
25. Oktober 2024 06:09 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market by Treatment Type, Disorder Type, Distribution Channel - Global Forecast 2025-2030" report has been added to ...
Desert Hope Treatment Center Promotes Kristin Berg to Executive Director, Solidifying its Position as a Market Leader
10. Juli 2024 12:10 ET
|
Desert Hope Treatment Center
LAS VEGAS, July 10, 2024 (GLOBE NEWSWIRE) -- Desert Hope Treatment Center, a leading addiction treatment provider in Las Vegas, is proud to announce the promotion of Kristin Berg to the position of...
Behavioral Health Market revenue to surpass USD 67 Billion by 2033, says Research Nester
22. Januar 2024 05:00 ET
|
Research Nester
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global behavioral health market size is projected to expand at ~5% CAGR between 2023 and 2033. The market is expected to garner a revenue of USD 67...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
09. November 2023 09:20 ET
|
Clearmind Medicine Inc.
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada,...
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
01. August 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
22. Mai 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
28. Dezember 2022 09:00 ET
|
Clearmind Medicine Inc.
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE...
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
13. Dezember 2022 09:00 ET
|
Clearmind Medicine Inc.
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,CSE:...